Compare 10X Genomics Inc (TXG) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Zscaler Inc — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.55B), while Zscaler Inc trades at $166.58 (market cap $26.41B). The key difference: Zscaler Inc is far larger — about 3.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| TXG | ZS | |
|---|---|---|
Market Cap | $8.55B | $26.41B |
Sector | Health | Technology |
52-Week High | $67.29 | $336.27 |
52-Week Low | $11.34 | $118.05 |
Enterprise Value | $8.08B | $24.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Zscaler (ZS) trades at $161.94, down 4.63% today, reflecting bearish technical signals despite strong quarterly earnings beats. Revenue growth remains robust at 25% year-over-year in Q4 2026, though net income margins are negative. The stock faces headwinds from slowing growth guidance for FY2027 and elevated valuation multiples, with a consensus price target of $204.88 suggesting 26% upside. Recent news highlights AI security product launches and conference presentations.
Outlook is mixed: analyst sentiment is overwhelmingly bullish (79% buy ratings), but execution risks and decelerating top-line growth cloud near-term performance. Investment opportunity hinges on AI-driven cybersecurity demand offsetting margin pressures, while risks include competitive threats and capital expenditure increases impacting cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
